N@N

Protalix BioTherapeutics to Present at the Opening Plenary Session of the Plant and Animal Genome XVII Conference

^{Published on 2009-01-05 05:31:18, Last Modified on 2009-01-05 05:31:49 - Market Wire}
 

CARMIEL, Israel--([ BUSINESS WIRE ])--Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will be presenting at the Plant and Animal Genome XVII Conference, January 11-14, 2009 at the Town and Country Convention Center in San Diego, California. Dr. Aviezer's presentation entitled, "Expression of therapeutic proteins in genetically engineered plant cells - Gaucher disease case study" will be the keynote presentation at the opening plenary session on Sunday, January 11, 2009 at 6:15 PM PT. The Plant and Animal Genome Conference brings together leading genetic scientists and researchers. More than 2,000 attendees are expected from over 30 countries.

About Protalix BioTherapeutics

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is conducting a phase III pivotal study for its lead product candidate, prGCD, to be used in enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans. Protalix has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix has completed enrollment for this study and is treating patients in its pivotal phase III clinical trial in North America, South America, Israel, Europe and South Africa. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.